Published in J Histochem Cytochem on August 01, 1989
Curli biogenesis and function. Annu Rev Microbiol (2006) 4.77
Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A (1999) 4.71
The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell (2012) 4.29
Functional amyloid formation within mammalian tissue. PLoS Biol (2006) 3.92
Sequential mechanism of solubilization and refolding of stable protein aggregates by a bichaperone network. Proc Natl Acad Sci U S A (1999) 3.33
An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated beta-sheet structure for amyloid. Proc Natl Acad Sci U S A (2001) 3.26
De novo amyloid proteins from designed combinatorial libraries. Proc Natl Acad Sci U S A (1999) 2.38
A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A (1994) 2.27
The toxicity in vitro of beta-amyloid protein. Biochem J (1995) 2.17
Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A (1996) 1.97
The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. Proc Natl Acad Sci U S A (2007) 1.97
Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci U S A (2004) 1.83
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A (2007) 1.68
The crystal structure of a 3D domain-swapped dimer of RNase A at a 2.1-A resolution. Proc Natl Acad Sci U S A (1998) 1.59
Towards a pharmacophore for amyloid. PLoS Biol (2011) 1.58
Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J Chem Biol (2009) 1.55
Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A (2006) 1.49
A systematic screen of beta(2)-microglobulin and insulin for amyloid-like segments. Proc Natl Acad Sci U S A (2006) 1.49
Protein engineering as a strategy to avoid formation of amyloid fibrils. Protein Sci (2000) 1.46
Increasing the amphiphilicity of an amyloidogenic peptide changes the beta-sheet structure in the fibrils from antiparallel to parallel. Biophys J (2004) 1.41
Interactions of the chaperone Hsp104 with yeast Sup35 and mammalian PrP. Proc Natl Acad Sci U S A (1997) 1.34
Short protein segments can drive a non-fibrillizing protein into the amyloid state. Protein Eng Des Sel (2009) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Effect of acid predissolution on fibril size and fibril flexibility of synthetic beta-amyloid peptide. Biophys J (1994) 1.28
N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J Biol Chem (2009) 1.28
Imaging linear birefringence and dichroism in cerebral amyloid pathologies. Proc Natl Acad Sci U S A (2003) 1.26
Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci (1999) 1.25
Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr (2005) 1.25
Light scattering analysis of fibril growth from the amino-terminal fragment beta(1-28) of beta-amyloid peptide. Biophys J (1993) 1.25
A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem (2010) 1.22
The binding of thioflavin T and its neutral analog BTA-1 to protofibrils of the Alzheimer's disease Abeta(16-22) peptide probed by molecular dynamics simulations. J Mol Biol (2008) 1.22
Reelin molecules assemble together to form a large protein complex, which is inhibited by the function-blocking CR-50 antibody. Proc Natl Acad Sci U S A (2000) 1.18
Amyloid as a depot for the formulation of long-acting drugs. PLoS Biol (2008) 1.17
Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity. J Am Chem Soc (2010) 1.15
In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect. J Diabetes Sci Technol (2010) 1.14
Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. Protein Sci (2001) 1.13
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One (2011) 1.10
Synthesis of a library of oligothiophenes and their utilization as fluorescent ligands for spectral assignment of protein aggregates. Org Biomol Chem (2011) 1.08
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A (1995) 1.08
Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. Protein Sci (2006) 1.07
The Japanese mutant Aβ (ΔE22-Aβ(1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type Aβ(1-40) into atypical fibrils by ΔE22-Aβ(1-39). Biochemistry (2011) 1.05
Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-beta aggregates. Proc Natl Acad Sci U S A (2010) 1.01
In vivo evidence for the fibrillar structures of Sup35 prions in yeast cells. J Cell Biol (2010) 1.00
Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci (2011) 0.98
Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med (2008) 0.98
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry (2006) 0.98
Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. ACS Chem Neurosci (2012) 0.96
Characterization of the native and fibrillar conformation of the human Nalpha-acetyltransferase ARD1. Protein Sci (2006) 0.96
Existence of different structural intermediates on the fibrillation pathway of human serum albumin. Biophys J (2009) 0.95
Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol (2004) 0.94
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta. Bioorg Med Chem Lett (2009) 0.90
Binding of Congo red to amyloid protofibrils of the Alzheimer Aβ(9-40) peptide probed by molecular dynamics simulations. Biophys J (2012) 0.88
CD14 protein acts as an adaptor molecule for the immune recognition of Salmonella curli fibers. J Biol Chem (2013) 0.88
Curcumin as an amyloid-indicator dye in E. coli. Chem Commun (Camb) (2013) 0.88
E. coli chaperones DnaK, Hsp33 and Spy inhibit bacterial functional amyloid assembly. Prion (2011) 0.87
Formation kinetics of insulin-based amyloid gels and the effect of added metalloporphyrins. Biophys J (2005) 0.86
Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett (2009) 0.85
Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein. Biophys J (2008) 0.84
Structurally distinct toxicity inhibitors bind at common loci on β-amyloid fibril. Protein Sci (2010) 0.82
Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol (2013) 0.82
A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. PLoS One (2013) 0.82
Engineering fluorogen activating proteins into self-assembling materials. Bioconjug Chem (2013) 0.82
Identification of the protein target of myelin-binding ligands by immunohistochemistry and biochemical analyses. J Histochem Cytochem (2012) 0.82
Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm (2013) 0.82
Measurement of amyloid formation by turbidity assay-seeing through the cloud. Biophys Rev (2016) 0.81
Modelling of amyloid beta-peptide induced lesions using roller-drum incubation of hippocampal slice cultures from neonatal rats. Exp Brain Res (2005) 0.80
Acridine derivatives inhibit lysozyme aggregation. Eur Biophys J (2008) 0.80
Structural elements regulating amyloidogenesis: a cholinesterase model system. PLoS One (2008) 0.80
The response of cerebral cortex to haemorrhagic damage: experimental evidence from a penetrating injury model. PLoS One (2013) 0.80
Ribonuclease A suggests how proteins self-chaperone against amyloid fiber formation. Protein Sci (2011) 0.80
Different factors affecting human ANP amyloid aggregation and their implications in congestive heart failure. PLoS One (2011) 0.80
Influence of pH control in the formation of inclusion bodies during production of recombinant sphingomyelinase-D in Escherichia coli. Microb Cell Fact (2014) 0.79
Nanoscopic and photonic ultrastructural characterization of two distinct insulin amyloid states. Int J Mol Sci (2012) 0.79
Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin. Proteins (2012) 0.79
Self-assembly of human latexin into amyloid-like oligomers. BMC Struct Biol (2007) 0.79
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Sci Rep (2016) 0.78
Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice. Lett Drug Des Discov (2009) 0.78
Quantifying prefibrillar amyloids in vitro by using a "thioflavin-like" spectroscopic method. Chembiochem (2010) 0.78
The Rho Termination Factor of Clostridium botulinum Contains a Prion-Like Domain with a Highly Amyloidogenic Core. Front Microbiol (2016) 0.78
A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5×-familial Alzheimer's disease mice. Histochem Cell Biol (2016) 0.77
Molecular modeling to investigate the binding of Congo red toward GNNQQNY protofibril and in silico virtual screening for the identification of new aggregation inhibitors. J Mol Model (2012) 0.77
Mammalian prion protein (PrP) forms conformationally different amyloid intracellular aggregates in bacteria. Microb Cell Fact (2015) 0.77
Ionic self-complementarity induces amyloid-like fibril formation in an isolated domain of a plant copper metallochaperone protein. BMC Struct Biol (2004) 0.77
Identification and characterization of a compound from Cuminum cyminum essential oil with antifibrilation and cytotoxic effect. Res Pharm Sci (2015) 0.77
Effects of mutations in yeast prion [PSI+] on amyloid toxicity manifested in Escherichia coli strain BL21. Prion (2008) 0.77
The influence of phospholipid membranes on bovine calcitonin secondary structure and amyloid formation. Protein Sci (2005) 0.76
Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation. Biochem Biophys Res Commun (2009) 0.76
Cooperative stabilization of transthyretin by clusterin and diflunisal. Biochemistry (2014) 0.76
The Luminescent Oligothiophene p-FTAA Converts Toxic Aβ1-42 Species into Nontoxic Amyloid Fibers with Altered Properties. J Biol Chem (2016) 0.76
Dissecting the contribution of Staphylococcus aureus α-phenol-soluble modulins to biofilm amyloid structure. Sci Rep (2016) 0.75
Lens Endogenous Peptide αA66-80 Generates Hydrogen Peroxide and Induces Cell Apoptosis. Aging Dis (2017) 0.75
Immunoprecipitation of amyloid fibrils by the use of an antibody that recognizes a generic epitope common to amyloid fibrils. PLoS One (2014) 0.75
An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. Sci Rep (2016) 0.75
The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. Acta Neuropathol Commun (2016) 0.75
Dispersion of single-wall carbon nanotubes with supramolecular Congo red - properties of the complexes and mechanism of the interaction. Beilstein J Nanotechnol (2017) 0.75
Generating local amyloidosis in mice by the subcutaneous injection of human insulin amyloid fibrils. Exp Ther Med (2014) 0.75
Mechanisms for the inhibition of amyloid aggregation by small ligands. Biosci Rep (2016) 0.75
Smooth muscle titin forms in vitro amyloid aggregates. Biosci Rep (2016) 0.75
Characterization of Soft Amyloid Cores in Human Prion-Like Proteins. Sci Rep (2017) 0.75
Amyloid sarcomeric proteins of the titin family. Dokl Biochem Biophys (2008) 0.75
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal (2009) 2.00
Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res (1994) 1.77
Hydrophobicity: is LogP(o/w) more than the sum of its parts? Eur J Med Chem (2000) 1.68
Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol (2001) 1.55
The enigma of the liganded hemoglobin end state: a novel quaternary structure of human carbonmonoxy hemoglobin. Biochemistry (2005) 1.54
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Two simple methods for quantifying low-affinity dye-substrate binding. J Histochem Cytochem (1989) 1.45
Changes in caudate volume with neuroleptic treatment. Lancet (1994) 1.43
Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum (2002) 1.40
Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? J Psychiatr Res (1998) 1.39
HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aided Mol Des (1991) 1.37
Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatry (1998) 1.35
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology (1996) 1.24
Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum (1999) 1.15
Abnormalities of the corpus callosum in first episode, treatment naive schizophrenia. J Neurol Neurosurg Psychiatry (2002) 1.13
N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology (1992) 1.13
Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging (1995) 1.11
A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry (1993) 1.11
Landmark-based morphometric analysis of first-episode schizophrenia. Biol Psychiatry (1999) 1.11
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J (2009) 1.08
Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry (2000) 1.07
Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci (1998) 1.06
Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors. J Med Chem (1991) 1.06
Fluorescence spectroscopy on Huntington's fibroblasts. J Neurochem (1979) 1.04
P-31 nuclear magnetic resonance analysis of brain: the perchloric acid extract spectrum. J Neurochem (1982) 1.03
Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging (1996) 1.02
X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with FMN at 1.8 A resolution. Structure (2000) 1.00
Swainsonine affects the processing of glycoproteins in vivo. FEBS Lett (1983) 1.00
Model systems for interacting heme moieties. II. The ferriheme octapeptide of cytochrome c. J Am Chem Soc (1967) 0.98
Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol (1998) 0.97
Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) (2005) 0.97
The X-ray structure determination of bovine carbonmonoxy hemoglobin at 2.1 A resoultion and its relationship to the quaternary structures of other hemoglobin crystal froms. Protein Sci (2001) 0.95
Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part II. Biol Psychiatry (2000) 0.95
Physiological and x-ray studies of potential antisickling agents. Proc Natl Acad Sci U S A (1983) 0.95
Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol (1998) 0.95
Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging (1996) 0.95
High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci (2001) 0.93
31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations. J Neuropathol Exp Neurol (1987) 0.93
Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae). J Pharm Sci (1972) 0.93
Structure of human erythrocyte catalase. Acta Crystallogr D Biol Crystallogr (2000) 0.92
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum (1997) 0.92
In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology (1989) 0.91
A comparison of stereology and segmentation techniques for volumetric measurements of lateral ventricles in magnetic resonance imaging. Psychiatry Res (1995) 0.91
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents. J Med Chem (1991) 0.89
Computational methodology for estimating changes in free energies of biomolecular association upon mutation. The importance of bound water in dimer-tetramer assembly for beta 37 mutant hemoglobins. Biochemistry (2000) 0.89
Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with atp-dependent glutamate uptake. J Biol Chem (1996) 0.88
Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo 31P MRS study. Mol Psychiatry (2003) 0.88
Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am J Physiol (1993) 0.87
Bisaldehyde allosteric effectors as molecular ratchets and probes. Biochemistry (1995) 0.87
Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) (2006) 0.86
Expression and function of heterotypic adhesion molecules during differentiation of human skeletal muscle in culture. Am J Pathol (1992) 0.86
Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiol Aging (1999) 0.86
Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood (2001) 0.86
Very empirical treatment of solvation and entropy: a force field derived from log Po/w. J Comput Aided Mol Des (2001) 0.85
Increased angiogenic response but deficient arteriolization and abnormal microvessel ultrastructure in critical leg ischaemia. Br J Surg (2006) 0.85
Design, synthesis, and testing of antisickling agents. 2. Proline derivatives designed for the donor site. J Med Chem (1983) 0.85
Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part I. Biol Psychiatry (2000) 0.85
Oral itraconazole therapy for mycotic keratitis. Mycoses (1988) 0.85
Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J Comput Aided Mol Des (1994) 0.85
Magnetic resonance spectroscopy in psychiatry: potential, pitfalls, and promise. Am J Psychiatry (1991) 0.84
Comparison of crystal and solution hemoglobin binding of selected antigelling agents and allosteric modifiers. Biochemistry (1990) 0.84
Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol (1998) 0.84
Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo. J Pharmacol Exp Ther (1982) 0.84
Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J Virol (1995) 0.83
Design, synthesis, and testing of potential antisickling agents. 1. Halogenated benzyloxy and phenoxy acids. J Med Chem (1982) 0.83
Low-affinity hemoglobin increases tissue PO2 and decreases arteriolar diameter and flow in the rat cremaster muscle. Microvasc Res (1996) 0.83
Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo (31)P brain spectra. Magn Reson Med (2001) 0.83
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site. J Med Chem (1984) 0.83
X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin. Proc Natl Acad Sci U S A (1991) 0.83
KEY, LOCK, and LOCKSMITH: complementary hydropathic map predictions of drug structure from a known receptor-receptor structure from known drugs. J Mol Graph (1992) 0.82
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. Br J Psychiatry Suppl (1998) 0.82
Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM (1998) 0.82
Elevated phosphocholine and phosphatidylcholine following rat entorhinal cortex lesions. Neurobiol Aging (1997) 0.82
Stability of CSF metabolites measured by proton NMR. J Neural Transm (Vienna) (2000) 0.82
Oral ketoconazole in Keratomycosis. Indian J Ophthalmol (1989) 0.82
Management of degenerative disc disease above an L5-S1 segment requiring arthrodesis. Spine (Phila Pa 1976) (1999) 0.82
Studies of the fluorescence of fibroblasts from Huntington's disease: evidence of a membrane abnormality. N Engl J Med (1979) 0.81
NMR identification of the formic acid-modified residue in Alzheimer's amyloid protein. J Neurochem (1994) 0.81
Alzheimer's beta-amyloid protein is covalently modified when dissolved in formic acid. J Neurochem (1990) 0.81
Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol (1998) 0.80
Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls. Neurochem Res (1993) 0.80
QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction. Proteins (2001) 0.80
Possible roles of L-phosphoserine in the pathogenesis of Alzheimer's disease. Mol Chem Neuropathol (1991) 0.80
Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. J Lipid Mediat Cell Signal (1996) 0.80
Membrane studies in Huntington's disease: steady state and time-dependent fluorescence spectroscopy of intact lymphocytes. J Neurochem (1981) 0.80
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids. J Med Chem (1984) 0.80
Evaluation of the side arm of (naphthylvinyl)pyridinium inhibitors of choline acetyltransferase. J Med Chem (1988) 0.80
Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol (2004) 0.79
RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Am J Physiol (1996) 0.79
Reactions of sulfenes with ketene acetals and ketene animals. J Org Chem (1967) 0.79
Filamentous proteins in Alzheimer's disease: new insights through molecular biology. Psychiatr Dev (1988) 0.79
L-phosphoserine, a metabolite elevated in Alzheimer's disease, interacts with specific L-glutamate receptor subtypes. J Neurochem (1991) 0.79
Itraconazole therapy for fungal keratitis. Indian J Ophthalmol (1987) 0.79